» Articles » PMID: 37620424

HCT Frailty Scale for Younger and Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Abstract

The HCT Frailty Scale is an easy prognostic tool composed of (a) Clinical Frailty Scale; (b) Instrumental Activities of Daily Living; (c) Timed-up-and-Go test; (d) Grip Strength; (e) Self-Health Rated Questionnaire; (f) Falls tests; (g) Albumin and C-reactive protein levels. This scale was designed to classify allogeneic hematopoietic cell transplant (alloHCT) candidates into fit, pre-frail and frail groups, irrespective of age. This study evaluates the ability of this frailty classification to predict overall survival (OS) and non-relapse mortality (NRM) in adult patients of all ages, in a prospective sample of 298 patients transplanted between 2018 and 2020. At first consultation, 103 (34.6%) patients were fit, 148 (49.7%) pre-frail, and 47 (15.8%) were frail. The 2-year OS and NRM of the three groups were 82.9%, 67.4%, and 48.3% (P < 0.001), and 5.4%, 19.2%, and 37.7% (P < 0.001). For patients younger than 60 years (n = 174), the 2-year OS and NRM of fit, pre-frail, and frail groups were 88.4%, 69.3% and 53.1% (P = 0.002), and 5.8%, 22.8%, and 34.8% (P = 0.005), respectively; and in patients older than 60 (n = 124), OS and NRM were 75.5%, 63.8% and 41.4% (P = 0.006), and 4.9%, 16.4%, and 42.1% (P = 0.001). In conclusion, frailty predicted worse transplant outcomes in both younger and older adults.

Citing Articles

Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care.

Salas M, Solano M, Baile Gonzalez M, Acera Gomez M, Fox L, Perez Artigas M Front Immunol. 2025; 15():1512154.

PMID: 39840039 PMC: 11747426. DOI: 10.3389/fimmu.2024.1512154.


Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT.

Polverelli N, Hernandez-Boluda J, Gagelmann N, Gurnari C, Malagola M, Duarte F Bone Marrow Transplant. 2024; 60(1):10-18.

PMID: 39402189 DOI: 10.1038/s41409-024-02437-6.

References
1.
Passweg J, Baldomero H, Chabannon C, Basak G, de la Camara R, Corbacioglu S . Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021; 56(7):1651-1664. PMC: 8263343. DOI: 10.1038/s41409-021-01227-8. View

2.
Snowden J, Sanchez-Ortega I, Corbacioglu S, Basak G, Chabannon C, de la Camara R . Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022; 57(8):1217-1239. PMC: 9119216. DOI: 10.1038/s41409-022-01691-w. View

3.
Abel G, Klepin H . Frailty and the management of hematologic malignancies. Blood. 2017; 131(5):515-524. DOI: 10.1182/blood-2017-09-746420. View

4.
Scheepers E, Vondeling A, Thielen N, van der Griend R, Stauder R, Hamaker M . Geriatric assessment in older patients with a hematologic malignancy: a systematic review. Haematologica. 2020; 105(6):1484-1493. PMC: 7271571. DOI: 10.3324/haematol.2019.245803. View

5.
Klepin H . Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice. Blood. 2019; 134(23):2005-2012. DOI: 10.1182/blood.2019001299. View